Opinion/decision on a Paediatric investigation plan (PIP): Epidyolex, cannabidiol, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Neurology, PIP number: P/0095/2020

EMEA-001964-PIP03-21

Human medicines European public assessment report (EPAR): Bemfola, follitropin alfa, Date of authorisation: 26/03/2014, Revision: 12, Status: Authorised

EMEA-002142-PIP01-17

EMEA-000977-PIP01-10

EMEA-003277-PIP02-23

PSUSA/00000535/202504

Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Date of authorisation: 19/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Trabectedin Accord, trabectedin, Date of authorisation: 25/04/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Accord, bortezomib, Date of authorisation: 20/07/2015, Revision: 17, Status: Authorised